Pollini Robin A
J Am Pharm Assoc (2003). 2017 Nov-Dec;57(6):677-685. doi: 10.1016/j.japh.2017.06.017. Epub 2017 Aug 12.
California Senate Bill 41 (SB41), effective January 2012, is a human immunodeficiency virus/hepatitis C virus prevention measure designed to expand syringe access among injection drug users (IDUs) by allowing pharmacies to sell syringes without a prescription. This study assesses self-reported implementation of SB41 and characterizes barriers amenable to intervention.
Interviewer-administered survey.
Fresno and Kern Counties, CA. Pharmacists and other pharmacy staff (n = 404) at 212 pharmacies.
Self-reported nonprescription pharmacy sales to known or suspected IDUs.
Overall, 29.3% of participants said their pharmacy would sell nonprescription syringes to a known or suspected IDU, whereas a far higher proportion (79.3%) would sell nonprescription syringes to a person with diabetes. More than one-half said that their pharmacy requires nonprescription syringe purchasers to enter their signature and name and address in a log book although that is not required under SB41. Fewer than 2 out of 3 participants (61.1%) knew that it is legal to sell nonprescription syringes to IDUs. That knowledge, as well as having syringe sales practices based on both store policy and discretion, were positively associated with IDU syringe sales after controlling for other factors. Working at an independent pharmacy, agreeing that only people with "medical conditions" such as diabetes should be able to buy syringes, and viewing syringe sales to IDUs as "not good business" were independently but negatively associated with IDU syringe sales.
This study complements an earlier syringe purchase trial documenting low participation in voluntary nonprescription syringe sales under SB41 in Fresno and Kern Counties. In the absence of legislation requiring mandatory syringe sales, interventions should be developed to increase knowledge of the law and frame addiction as a medical condition, with a special focus on independent pharmacies. Informational interventions should stress the need to eliminate log book documentation requirements, which may serve as a barrier to IDU purchase.
加利福尼亚州参议院法案41(SB41)于2012年1月生效,是一项人类免疫缺陷病毒/丙型肝炎病毒预防措施,旨在通过允许药店在无处方的情况下销售注射器,扩大注射吸毒者(IDU)获取注射器的途径。本研究评估了SB41的自我报告实施情况,并确定了适合干预的障碍因素。
访谈员实施的调查。
加利福尼亚州弗雷斯诺县和克恩县。212家药店的药剂师和其他药房工作人员(n = 404)。
自我报告的向已知或疑似注射吸毒者进行非处方药店销售情况。
总体而言,29.3%的参与者表示他们的药店会向已知或疑似注射吸毒者销售非处方注射器,而向糖尿病患者销售非处方注射器的比例要高得多(79.3%)。超过一半的人表示,他们的药店要求非处方注射器购买者在日志簿上签名并填写姓名和地址,尽管SB41并未要求这样做。不到三分之二的参与者(61.1%)知道向注射吸毒者销售非处方注射器是合法的。在控制其他因素后,这种认知以及基于商店政策和自行决定的注射器销售做法与向注射吸毒者销售注射器呈正相关。在独立药店工作、认为只有患有糖尿病等“医疗状况”的人才能购买注射器以及将向注射吸毒者销售注射器视为“不良业务”与向注射吸毒者销售注射器呈独立但负相关。
本研究补充了一项早期注射器购买试验,该试验记录了弗雷斯诺县和克恩县在SB41下自愿非处方注射器销售的参与率较低。在没有强制注射器销售立法的情况下,应制定干预措施,以增加对法律的了解,并将成瘾视为一种医疗状况,特别关注独立药店。信息干预应强调消除日志簿记录要求的必要性,这可能成为注射吸毒者购买的障碍。